Cambridge, UK-based F-star has signed a new collaboration with Merck under which the drug giant has the option to develop and commercialise five of its bispecific immuno-oncology antibodies.
News
Precision ovarian cancer drug shows early promise
An experimental targeted treatment for ovarian cancer has shown promise in early clinical trials shrinking tumours in half of women with the disease.
EU clears Biogen’s Spinraza for rare spinal disorder
EU regulators have issued clearance for the first therapy to treat spinal muscular atrophy (SMA), a rare and often fatal genetic disease affecting muscle strength and movement.
ViiV/Janssen’s two-drug HIV regimen filed in US, EU
ViiV Healthcare has filed a single-tablet, two-drug regimen of its dolutegravir and Janssen’s rilpivirine with regulators in both the US and EU.
NICE backs Opdivo for classical Hodgkin lymphoma
Patients with classical Hodgkin lymphoma (cHL) living in England and Wales could now become the first to get routine access on the NHS to Bristol-Myers Squibb’s immunotherapy Opdivo after a u-turn saw cost regulators provisionally back the drug.
AZ’ Lynparza shows similar QoL to placebo
AstraZeneca has presented late-stage data showing that patients taking its ovarian cancer therapy Lynparza not only benefitted from improved progression-free survival but also reported similar quality of life to those taking a placebo.
Teva’s migraine drug hits key PhIII goal
Teva has unveiled data showing that its experimental migraine drug fremanezumab hit key efficacy targets in a late stage trial, on the back of which it expects to submit regulatory filings later this year.
EU review for Sandoz’ Humira, Remicade biosimilars
European regulators have accepted for review Sandoz’ marketing applications for biosimilars to AbbVie’s Humira (adalimumab) and Janssen’s Remicade (infliximab).
NICE u-turn backs Sanofi’s Gaucher disease drug
It is now looking likely that Sanofi’s Cerdelga will be funded on the NHS in England and Wales to treat type 1 Gaucher disease, after a u-turn by cost regulators.
Bicycle raises £40m to advance pipeline
UK biotech Bicycle Therapeutics has raised an impressive £40 million to help advance its lead candidate, cancer drug BT1718, into the clinic trials later this year.
Expats returning post Brexit could cost NHS £500m
The NHS could be faced with having to pay nearly half a billion pounds more if British expats decide to return to the UK because their right to healthcare in EU countries is withdrawn after Brexit.
EU nod for Pfizer’s men B jab Trumenba
Pfizer’s Trumenba has been cleared by European regulators to help prevent infection with meningococcal group B disease in adolescents and adults.
Gilead’s HIV drug ‘non-inferior’ to ViiV’s Tivicay
Gilead has unveiled data from a batch of late-stage trials showing that its investigational HIV therapy bictegravir was non-inferior to ViiV Healthcare’s flagship drug dolutegravir in suppressing levels of the virus.
NICE backs Keytruda for first and second-line use
MSD’s Keytruda has now become the first and only immunotherapy to be recommended by the National Institute for Health and Care Excellence as a first and second line treatment for specific populations of patients with lung cancer.
Report highlights value of EU-UK research partnerships
Leading medical organisations in the UK are calling for continued collaboration between researchers in the UK and Europe during and after Brexit as a new reports highlights the value of such partnerships and their benefit to patients.
